Home The Word Brain My Amedeo FAQ Privacy About   


Hanzi Hunter — ultra-fast Hanzi study

All 1,152 characters from the aioLingua manual

AbstractAboutThe 20 audio files

← aioLingua Chinese Online

← Chinese aioLingua PDF


  Diabetes

  Free Subscription


Articles published in J Clin Invest

Retrieve available abstracts of 44 articles:
HTML format



Single Articles


    December 2025
  1. BLACK PN, DiRusso CC
    FATP2 at the crossroads of fatty acid transport, lipotoxicity, and complex disease.
    J Clin Invest. 2025;135:e199873.
    PubMed     Abstract available


  2. EIZIRIK DL, Zimath PL
    Diabetes research enters the biobank era: searching for the truth in a deep well.
    J Clin Invest. 2025;135:e199728.
    PubMed     Abstract available


  3. KHAN S, Gaivin RJ, Liu Z, Li V, et al
    Fatty acid transport protein 2 inhibition enhances glucose tolerance through alpha cell-mediated GLP-1 secretion.
    J Clin Invest. 2025;135:e192011.
    PubMed     Abstract available


    November 2025
  4. WU L, Wentworth JM, Liddle C, Fewings N, et al
    Pancreatic volume and immune biomarkers predict checkpoint inhibitor-associated autoimmune diabetes in humans.
    J Clin Invest. 2025 Nov 20:e192938. doi: 10.1172/JCI192938.
    PubMed     Abstract available


  5. BHAGCHANDANI P, Ramos SA, Rodriguez B, Gu X, et al
    Curing autoimmune diabetes in mice with islet and hematopoietic cell transplantation after CD117 antibody-based conditioning.
    J Clin Invest. 2025 Nov 18:e190034. doi: 10.1172/JCI190034.
    PubMed     Abstract available


  6. VALENCIA-RINCON E, Rai R, Chandra V, Wellberg EA, et al
    GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research.
    J Clin Invest. 2025;135:e194743.
    PubMed     Abstract available


  7. COOPER ME, van Raalte DH
    GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity.
    J Clin Invest. 2025;135:e194749.
    PubMed     Abstract available


  8. WONG CK, Drucker DJ
    Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits.
    J Clin Invest. 2025;135:e194751.
    PubMed     Abstract available


  9. TAMBRALLI A, Knight JS
    Neutrophils take center stage in VEXAS syndrome pathogenesis.
    J Clin Invest. 2025;135:e199299.
    PubMed     Abstract available


    October 2025
  10. KATZ LS, Scott DK, Stewart AF
    SIRT2 puts the brakes on human beta cell proliferation: therapeutic opportunities and next challenges.
    J Clin Invest. 2025;135:e197142.
    PubMed     Abstract available


    September 2025
  11. SASSI G, Lemaitre P, Fernandez Calvo L, Lodi F, et al
    Neutrophil-enriched gene signature correlates with teplizumab therapy resistance in different stages of type 1 diabetes.
    J Clin Invest. 2025 Sep 30:e176403. doi: 10.1172/JCI176403.
    PubMed     Abstract available


  12. DOS SANTOS T, Dai XQ, Jones RC, Spigelman AF, et al
    Altered immune and metabolic molecular pathways drive islet cell dysfunction in human type 1 diabetes.
    J Clin Invest. 2025 Sep 30:e195267. doi: 10.1172/JCI195267.
    PubMed     Abstract available


  13. VIRGILIO E, Tielens S, Bonfield G, Nian FS, et al
    Recessive TMEM167A variants cause neonatal diabetes, microcephaly and epilepsy syndrome.
    J Clin Invest. 2025 Sep 9:e195756. doi: 10.1172/JCI195756.
    PubMed     Abstract available


  14. MEAKIN PJ, Coull BM, Tuharska Z, McCaffery C, et al
    Expression of Concern for Elevated circulating amyloid concentrations in obesity and diabetes promote vascular dysfunction.
    J Clin Invest. 2025;135:e199125.
    PubMed    


    August 2025
  15. TAVARES-FERREIRA D, Shen BQ, Mwirigi JM, Shiers S, et al
    Cell and molecular profiles in peripheral nerves shift toward inflammatory phenotypes in diabetic peripheral neuropathy.
    J Clin Invest. 2025 Aug 19:e184075. doi: 10.1172/JCI184075.
    PubMed     Abstract available


  16. KONG YX, Rehan R, Moreno CL, Madsen S, et al
    SEC61B regulates calcium flux and platelet hyperreactivity in diabetes.
    J Clin Invest. 2025;135:e184597.
    PubMed     Abstract available


  17. MIRZADEH Z, Morton GJ, Hirsch IB, Schwartz MW, et al
    An unexpected role for the brain in the pathogenesis of diabetic ketoacidosis.
    J Clin Invest. 2025;135:e196357.
    PubMed    


  18. CHOE J, Belmonte P, Crotts S, Nguyen T, et al
    ST8Sia6 overexpression protects pancreatic beta cells from spontaneous autoimmune diabetes in nonobese diabetic mice.
    J Clin Invest. 2025;135:e181207.
    PubMed     Abstract available


    July 2025
  19. SINGH AK, Bernabucci M, Dvorak NM, Haghighijoo Z, et al
    Sensory neuron-expressed FGF13 controls nociceptive signaling in diabetic neuropathy models.
    J Clin Invest. 2025;135:e183749.
    PubMed     Abstract available


  20. LI X, Hu J, Huang Y, Zhang H, et al
    Trapalpha deficiency impairs the early events of insulin biosynthesis and glucose homeostasis.
    J Clin Invest. 2025;135:e179845.
    PubMed     Abstract available


  21. NEWSOME PN, Loomba R
    Therapeutic horizons in metabolic dysfunction-associated steatohepatitis.
    J Clin Invest. 2025;135:e186425.
    PubMed     Abstract available


    June 2025
  22. TOMLINSON JW
    Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome?
    J Clin Invest. 2025;135:e191822.
    PubMed     Abstract available


    May 2025
  23. COSTANTINO S, Mohammed SA, Paneni F
    Endothelial dysfunction in patients with type 2 diabetes: the truth is in the blood.
    J Clin Invest. 2025;135:e193128.
    PubMed     Abstract available


  24. SARKAR M, Kushner T
    Metabolic dysfunction-associated steatotic liver disease and pregnancy.
    J Clin Invest. 2025;135:e186426.
    PubMed     Abstract available


  25. GOU Y, Glat M, Damian V, Bryan CL, et al
    AgRP neuron hyperactivity drives hyperglycemia in a mouse model of type 2 diabetes.
    J Clin Invest. 2025;135:e189842.
    PubMed     Abstract available


  26. PETRIE GN, Mayo LM
    GLP-1 receptor agonists for the treatment of alcohol use disorder.
    J Clin Invest. 2025;135:e192414.
    PubMed     Abstract available


    April 2025
  27. GATTU AK, Tanzer M, Yaron-Barir TM, Johnson JL, et al
    Cell-intrinsic insulin signaling defects in human iPS cell-derived hepatocytes in type 2 diabetes.
    J Clin Invest. 2025;135:e183513.
    PubMed     Abstract available


    March 2025
  28. COLLADO A, Humoud R, Kontidou E, Eldh M, et al
    Erythrocyte-derived extracellular vesicles induce endothelial dysfunction through arginase-1 and oxidative stress in type 2 diabetes.
    J Clin Invest. 2025 Mar 20:e180900. doi: 10.1172/JCI180900.
    PubMed     Abstract available


    December 2024
  29. CATTIN-ROY AN, Laffey KG, Le LB, Schrum AG, et al
    Reduced thymic IL-4 impairs negative T cell selection in nonobese diabetic mice.
    J Clin Invest. 2024;134:e163417.
    PubMed     Abstract available


    October 2024
  30. CHOI YJ, Richard G, Zhang G, Hodgin JB, et al
    Attenuated kidney oxidative metabolism in young adults with type 1 diabetes.
    J Clin Invest. 2024 Oct 22:e183984. doi: 10.1172/JCI183984.
    PubMed     Abstract available


  31. OTENG AB, Liu L, Cui Y, Gavrilova O, et al
    Activation of Gs signaling in mouse enteroendocrine K-cells greatly improves obesity- and diabetes-related metabolic deficits.
    J Clin Invest. 2024 Oct 22:e182325. doi: 10.1172/JCI182325.
    PubMed     Abstract available


    September 2024
  32. DOLTON G, Bulek A, Wall A, Thomas H, et al
    HLA A*24:02-restricted T cell receptors cross-recognize bacterial and preproinsulin peptides in type 1 diabetes.
    J Clin Invest. 2024;134:e164535.
    PubMed     Abstract available


  33. CAPERA J, Dustin ML
    Microbial mimics supersize the pathogenic self-response.
    J Clin Invest. 2024;134:e184046.
    PubMed     Abstract available


    August 2024
  34. STERLING JK, Rajesh A, Droho S, Gong J, et al
    Retinal perivascular macrophages regulate immune cell infiltration during neuroinflammation in mouse models of ocular disease.
    J Clin Invest. 2024;134:e180904.
    PubMed     Abstract available


  35. DING J, Nguyen AT, Lohman K, Hensley MT, et al
    LXR signaling pathways link cholesterol metabolism with risk for prediabetes and diabetes.
    J Clin Invest. 2024;134:e185290.
    PubMed    


  36. LLEDO-DELGADO A, Preston-Hurlburt P, Currie S, Clark P, et al
    Teplizumab induces persistent changes in the antigen-speci fi c repertoire in individuals at-risk for type 1 diabetes.
    J Clin Invest. 2024 Aug 13:e177492. doi: 10.1172/JCI177492.
    PubMed     Abstract available


    July 2024
  37. SCHRADER LA, Ronnekleiv-Kelly SM, Hogenesch JB, Bradfield CA, et al
    Circadian disruption, clock genes, and metabolic health.
    J Clin Invest. 2024;134:e170998.
    PubMed     Abstract available


    June 2024
  38. MURALIDHARAN C, Huang F, Enriquez JR, Wang JE, et al
    Inhibition of the eukaryotic initiation factor-2-alpha kinase PERK decreases risk of autoimmune diabetes in mice.
    J Clin Invest. 2024 Jun 18:e176136. doi: 10.1172/JCI176136.
    PubMed     Abstract available


  39. HAEMMERLE MW, Scota AV, Khosravifar M, Varney MJ, et al
    RNA-binding protein PCBP2 regulates pancreatic beta cell function and adaptation to glucose.
    J Clin Invest. 2024;134:e172436.
    PubMed     Abstract available


    May 2024
  40. DING J, Nguyen AT, Lohman K, Hensley MT, et al
    LXR signaling pathways link cholesterol metabolism with risk for prediabetes and diabetes.
    J Clin Invest. 2024;134:e173278.
    PubMed     Abstract available


  41. SABADELL-BASALLOTE J, Astiarraga B, Castano C, Ejarque M, et al
    SUCNR1 regulates insulin secretion and glucose elevates the succinate response in people with prediabetes.
    J Clin Invest. 2024;134:e173214.
    PubMed     Abstract available


    April 2024
  42. YANG J, Zhuang H, Li J, Nunez-Nescolarde AB, et al
    The secreted micropeptide C4orf48 enhances renal fibrosis via an RNA-binding mechanism.
    J Clin Invest. 2024;134:e178392.
    PubMed     Abstract available


    March 2024
  43. DI GIUSEPPE G, Soldovieri L, Ciccarelli G, Ferraro PM, et al
    Reduced incretin effect precedes diabetes development following duodenopancreatectomy in subjects without diabetes.
    J Clin Invest. 2024 Mar 12:e175133. doi: 10.1172/JCI175133.
    PubMed    


  44. DEFRONZO RA
    SGLT2 inhibitors: cardiorenal metabolic drugs for the ages.
    J Clin Invest. 2024;134:e177625.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.